摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-溴-5- 氟吡啶-2-羧酸甲酯 | 1210419-26-3

中文名称
6-溴-5- 氟吡啶-2-羧酸甲酯
中文别名
2-溴-3-氟-6-甲酸甲酯吡啶;6-溴-5-氟吡啶-2-羧酸甲酯;6-溴-5-氟-2-吡啶甲酸甲酯
英文名称
methyl 6-bromo-5-fluoropyridine-2-carboxylate
英文别名
methyl 6-bromo-5-fluoropicolinate
6-溴-5- 氟吡啶-2-羧酸甲酯化学式
CAS
1210419-26-3
化学式
C7H5BrFNO2
mdl
——
分子量
234.025
InChiKey
AYMMPTHLFMQVFH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    275.5±35.0 °C(Predicted)
  • 密度:
    1.660±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    39.2
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险性防范说明:
    P264,P270,P301+P312,P330
  • 危险性描述:
    H302,H315,H320,H335
  • 储存条件:
    室温

SDS

SDS:b6d9ab2925973ff5c9e5adeb01f7f711
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl 6-bromo-5-fluoropyridine-2-carboxylate
Synonyms: Methyl 6-bromo-5-fluoropicolinate

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 6-bromo-5-fluoropyridine-2-carboxylate
CAS number: 1210419-26-3

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H5BrFNO2
Molecular weight: 234.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-溴-5- 氟吡啶-2-羧酸甲酯 在 sodium tetrahydroborate 作用下, 以 甲醇 为溶剂, 以90 %的产率得到(6-bromo-5-fluoropyridin-2-yl)methanol
    参考文献:
    名称:
    [EN] CDK2 INHIBITORS AND USE THEREOF
    [FR] INHIBITEURS DE CDK2 ET LEUR UTILISATION
    摘要:
    本公开提供一种由结构式(I’)表示的化合物,或其药学上可接受的盐,或其立体异构体,以及它们在治疗与CDK2相关的疾病或障碍方面的用途。本公开还涉及含有相同化合物的组合物以及使用和制备相同化合物的方法。
    公开号:
    WO2022206888A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    NOVEL KINASE INHIBITORS
    摘要:
    本发明提供了如下式的化合物: 以及本文进一步描述的相关化合物,以及包含这些化合物的药物组合物。该发明还提供了使用这些化合物和组合物治疗与Pim激酶活性不良水平相关的疾病的方法,包括癌症和自身免疫性疾病。
    公开号:
    US20120225062A1
点击查看最新优质反应信息

文献信息

  • CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
    申请人:Genentech, Inc.
    公开号:US20140088117A1
    公开(公告)日:2014-03-27
    Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    公式I的环醚吡唑-4-基-杂环基-羧酰胺化合物,包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐,其中R2为环醚,X为噻唑基、吡啶基、吡啶基或嘧啶基,可用于抑制Pim激酶,并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I化合物进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病或相关病理条件的方法。
  • [EN] N-(3-PYRIDYL) BIARYLAMIDES AS KINASE INHIBITORS<br/>[FR] N- (3-PYRIDYL)-BIARYLAMIDES EN TANT QU'INHIBITEURS DE KINASE
    申请人:NOVARTIS AG
    公开号:WO2014033631A1
    公开(公告)日:2014-03-06
    The present invention provides a compound of formula (I): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.
    本发明提供了一种公式(I)的化合物:如本文所述,以及药用可接受的盐、对映异构体、旋转异构体、互变异构体或外消旋混合物。还提供了使用公式(I)的化合物治疗由PIM激酶介导的疾病或状况的方法,以及包含这些化合物的药物组合物。
  • [EN] PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRIDINEAMINE UTILES EN TANT QU'INHIBITEURS DE KINASE PIM
    申请人:INCYTE CORP
    公开号:WO2016196244A1
    公开(公告)日:2016-12-08
    The present disclosure describes pyridineamine compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer, immune disorders and other diseases. Formula (I).
    本公开描述了吡啶胺化合物,以及它们的组成和使用方法。这些化合物抑制Pim激酶的活性,并且在治疗与Pim激酶活性相关的疾病方面具有用途,例如癌症、免疫紊乱和其他疾病。公式(I)。
  • [EN] OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS OXÉPAN-2-YL-PYRAZOL-4-YL-HÉTÉROCYCLYLE-CARBOXAMIDE ET LEURS MÉTHODES D'UTILISATION
    申请人:HOFFMANN LA ROCHE
    公开号:WO2015140189A1
    公开(公告)日:2015-09-24
    Oxepan-2-yl pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    氧杂环戊烷-2-基吡唑-4-基杂环基甲酰胺化合物的化学式I,包括立体异构体、几何异构体、互变异构体和其药用可接受的盐,其中X为噻唑基、吡啶基、吡啶基或嘧啶基,用于抑制Pim激酶,并用于治疗由Pim激酶介导的癌症等疾病。公开了使用化合物I的方法,用于体外、原位和体内诊断、预防或治疗哺乳动物细胞中的这类疾病,或相关的病理条件。
  • Kinase inhibitors and methods of their use
    申请人:BURGER Matthew T.
    公开号:US20100056576A1
    公开(公告)日:2010-03-04
    New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    提供了一种新的化合物、组合物和抑制与人类或动物宿主肿瘤发生相关的莫洛尼激酶(PIM激酶)活性的方法。在某些实施例中,该化合物和组合物能有效抑制至少一种PIM激酶的活性。这些新的化合物和组合物可以单独使用,也可以与至少一种其他试剂联合使用,用于治疗由丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的疾病,如癌症。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-